Chemotherapy for pancreatic carcinoma

Cancer

Volumn 78, Issue 3 SUPPL., 1996, Pages 654-663

  Ahlgren, James D ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

chemotherapy; palliation; pancreatic cancer; quality of life; survival; tumor response

Indexed keywords

FLUOROURACIL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; HUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; QUALITY OF LIFE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FLUOROURACIL; HUMANS; LEUCOVORIN; PANCREATIC NEOPLASMS;

EID: 0030015038     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960801)78:3<654::AID-CNCR46>3.0.CO;2-V     Document Type: Article

References (74)

1. Moertel CG, Reitemeyer RJ. Advanced Gastrointestinal Cancer: Clinical Management and Chemotherapy. New York: Harper and Row, 1969.
2. Oken MM, Davis TE, Creech RH, McFadden ET, Tormey DC, Carbone PP, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:549-55.
3. Uren RF, Hutcherson RJ, Stephen MS, Wong J. Liver scanning in patients with suspected metastatic malignant disease. Med J Aust 1976;ii:477-80.
4. Warr D, McKinney S, Tannock I. Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response. J Clin Oncol 1984;2:1040-6.
5. Kartner N, Riorden JR, Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 1983;221:1285-8.
6. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84:7735-8.
7. Morrow CS, Cowan KH. Glutathione S-transferases and drug resistance. Cancer Cells 1990;2:15-22.
8. Ahlgren JD. Pancreatic cancer: chemotherapy of advanced disease. In: Ahlgren JD, Macdonald JS, editors. Gastrointestinal Oncology. Philadelphia: JB Lippincott, 1992:227-35.
9. DeCaprio JA, Mayer RJ, Gonin R, Arbuck SG. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinomas of the pancreas: results of a phase II trial. J Clin Oncol 1991;9:2128-33.
10. Crown J, Casper ES, Botet I, Murray P, Kelsen DP: Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol 1991;9:1682-6.
11. Pazdur R, Ajani JJ, Abbruzzese JL, Belt RJ, Dakhil SR, Dubovsky D, et al. Phase II evaluation of fluorouracil and recombinant α-2a-interferon in previously untreated patients with pancreatic adenocarcinoma. Cancer 1992;70:2073-6.
12. Scheithauer W, Pfeffel F, Kornek G, Marczell A, Wiltschke C, Funovics J. A phase II trial of fluorouracil, leucovorin, and recombinant alpha-2b-interferon in advanced adenocarcinoma of the pancreas. Cancer 1992;70:1864-6.
13. Ardalan B, Singh G, Silberman H. A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers. J Clin Oncol 1988;6:1053-8.
14. Rosvold E, Schilder RJ, Walczak J. Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer. Cancer Chemother Pharmacol 1992;29:305-8.
15. Tian E, Ardalan B, Benedetto P, Feun L, Morrell L, Waldman S, et al. A phase A II study of ahort term protracted infusion of high dose 5-fluorouracil (5-FU) with leucovorin (LV) and low dose phosphonacetyl-L-aspartic acid (PALA) in pancreatic carcinoma [abstract]. Proc Am Soc Clin Oncol 1992; 11:184.
16. Cornell GN, Cahow CE, Frey C, McSherry C, Beal JM. Clinical experience with 5-fluorouracil (NSC-19893) in the treatment of malignant disease. Cancer Chemother Rep 1960;9:23-30.
17. Hurley JD, Ellison EH. Treatment of advanced cancer with 5-fluorouracil. Ann Surg 1960;152:568-82.
18. Carter SK, Comis L. The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. Cancer Treat Rev 1975;2:193-214.
19. O'Connell MJ. Current status of chemotherapy for advanced pancreatic and gastric cancer. J Clin Oncol 1985;3:1032-9.
20. Moertel CG. Chemotherapy of gastrointestinal cancer. Clin Gastroenterol 1976;5:777-93.
21. Erlichman C, Fine S, Wong A, Elhakim T. A randomized trial of fluorouracil with folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1088;6:469-75.
22. Lokich JJ, Ahlgren JD, Gullo JJ, Phillips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol 1989;7:425-32.
23. Petrelli N, Douglass HO, Herrera L, Russell D, Stablein DM, Bruckner HW, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 1989;7:1419-26.
24. Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, et al. Biochemical modulation of fluorouracil: evidence of significant improvement in survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7:1407-18.
25. Petrelli N, Herrera L, Rustum Y, Burke P, Creaven P, Stulc J, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987; 5:1559-65.
26. Lokich JJ, Ahlgren JD, Cantrell J, Heim W, Wampler GL, Gullo JJ, et al. A prospective randomized comparison of protracted infusional 5-fluorouracil with or without weekly bolus cisplatin in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. Cancer 1991;67:14-9.
27. Wadler S, Schwartz EL, Goldman M, Lyver A, Rader M, Zimmerman M, et al. Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 1989;7:1769-75.
28. Kemeny N, Younes A, Seiter K, Kelsen D, Sammarco P, Adams L, et al. Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma: assessment of activity and toxicity. Cancer 1990;66:2470-5.
29. Pazdur R, Ajani JA, Patt YZ, Winn R, Jackson D, Shepard B, et al. A phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma. J Clin Oncol 1990;8:2027-31.
30. Schein PS, Lavin PT, Moertel CG, Frytak S, Hahn RG, O'Connell MJ, et al. Randomized phase II clinical trial of Adriamycin, methotrexate, and actinomycin-D in advanced measurable pancreatic carcinoma: a Gastrointestinal Tumor Study Group report. Cancer 1978;42:19-22.
31. Horton J, Gelber R, Engstrom P, Falkson G, Moertel C, Brodovsky H, et al. Trials of single agent and combination chemotherapy for advanced cancer of the pancreas. Cancer Treat Rep 1981;65:65-8.
32. Smith DB, Kenny JB, Scarffe JH, Maley WV. Phase II evaluation of melphalan in adenocarcinoma of the pancreas. Cancer Treat Rep 1985;69:917-8.
33. Loehrer PJ, Williams SD, Einhorn LH, Ansari R. Ifosfamide: an active drug in the treatment of adenocarcinoma of the pancreas. J Clin Oncol 1985;3:367-72.
34. Bernard S, Noble S, Wilcosky T, Ahlgren J, Smith FP. A phase II trial of ifosfamide (IFOS) plus N-acetyl cysteine (NAC) in metastatic measureable pancreatic carcinoma (PC) [abstract]. Proc Am Soc Clin Oncol 1986;5:328.
35. Ajani JA, Abbruzzese JL, Goudeau P, Faintuch JS, Yeomans AC, Boman BM, et al. Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas. J Clin Oncol 1988;6:1703-7.
36. Gastrointestinal Tumor Study Group: ifosfamide is an inactive substance in the treatment of pancreatic carcinoma. Cancer 1989;64:2010-3.
37. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. Therapy of gastrointestinal cancer with the nitrosoureas alone and in drug combination. Cancer Treat Rep 1976;60:729-32.
38. Moertel CG, Douglass HO, Hanley J, Carbone PP. Phase II study of methyl-CCNU in the treatment of advanced pancreatic carcinoma. Cancer Treat Rep 1976;60:1659-61.
39. Wils J, Bleiberg H, Blijham G, Dalesis O, Duez N, Lacave A, et al. Phase-II study of epirubicin in advanced adenocarcinoma of the pancreas. Eur J Cancer Clin Oncol 1985;21:191-4.
40. Gastrointestinal Tumor Study Group: Phase II trials of hexamethylmelamine, dianhydrogalactitol, razoxane, and beta-2′-deoxythioguanosine as single agents against advanced measurable tumors of the pancreas. Cancer Treat Rep 1985; 69:713-6.
41. Smith FP, Stablein DM, Schein PS. Phase II combination chemotherapy trials in advanced measureable pancreatic cancer [abstract]. Proc Am Soc Clin Oncol 1984;3:150.
42. Gad-El-Mawla N, Ziegler JL. Ifosfamide treatment of pancreatic cancer. Cancer Treat Rep 1981;65:357-8.
43. Gad-El-Mawla N. Ifosfamide in advanced pancreatic cancer: a 5-year experience. Cancer Chemother Pharmacol 1986; 18 (Suppl):55-6.
44. Macdonald JS, Schein PS, Woolley PV, Smythe T, Ueno W, Hoth D, et al. 5-Fluorouracil, doxorubicin and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 1980;93:533-6.
45. Douglass H, Lavin P, Goudsmit A, Klaassen DJ, Paul AR. An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU. Mitomycin-C, Adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277). J Clin Oncol 1984; 1372-81.
46. Smith FP, Hoth DF, Levin B, Karlin DA, Macdonald JS, Woolley PV III, et al. 5-Fluorouracil, Adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas. Cancer 1980;46:2014-8.
47. Bitran JD, Desser RK, Kazloff MF, Billings AA, Shapiro CM. Treatment of metastatic pancreatic and gastric adenocarcinomas with 5-fluorouracil, Adriamycin, and mitomycin C (FAM). Cancer Treat Rep 1979;63:2049-51.
48. Wiggans RG, Woolley PV, Macdonald JS, Smythe T, Ueno W, Schein PS. Phase II trial of streptozotocin, mitomycin-C and 5-fluorouracil (SMF) in the treatment of advanced pancreatic cancer. Cancer 1978;41:387-91.
49. Bukowski RM, Aberhalden RT, Hewlett JS. Phase II trial of streptozotocin, mitomycin-C and 5-fluorouracil in adenocarcinoma of the pancreas. Cancer Clin Trials 1980;3:321-4.
50. Bukowski RM, Balcerzak SP, O'Bryan RM, Bonnet JD, Chen TT. Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer: a Southwest Oncology Group study. Cancer 1983; 52:1577-82.
51. Smith FP, Stablein DM, Schein PS for the Gastrointestinal Tumor Study Group (GITSG). Phase II combination chemotherapy trials in advanced measurable pancreatic cancer [abstract]. Proc Am Soc Clin Oncol 1982;3:150.
52. Gastrointestinal Tumor Study Group. Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. J Clin Oncol 1986;4:1794-8.
53. Oster MW, Gray R, Panasci L, Perry MC. Chemotherapy for advanced pancreatic cancer: a comparison of 5-fluorouracil, Adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM). Cancer 1986;57:29-33.
54. Bukowski RM, Schacter LP, Groppe CW, Hewlett JS, Weick JK, Livingston RB. Phase II trial of 5-fluorouracil, Adriamycin, mitomycin C, and streptozotocin (FAM-S) in pancreatic carcinoma. Cancer 1982;50:197-200.
55. Smith FP, Rustgi VK, Schertz G, Woolley PV, Schein PS. Phase II study of 5-FU, doxorubicin, and mitomycin (FAM) and chlorozotocin in advanced measurable pancreatic cancer. Cancer Treat Rep 1982;66:2095-6.
56. Karlin DA, Stroehlein JR, Bennetts RW, Jones RD, Heifetz LJ, Mahal PS. Phase I-II study of the combination of 5-FU, doxorubicin, mitomycin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas. Cancer Treat Rep 1982; 66:1613-7.
57. Buroker T, Kim PN, Groppe C, McCracken J, O'Bryan R, Panettiere F, et al. 5-Fluorouracil infusion with mitomycin-C vs 5-FU infusion with methyl-CCNU in the treatment of advanced upper gastrointestinal cancer. Cancer 1979; 44:1215-21.
58. Moertel CG, Rubin J, O'Connell MJ, Schutt AI, Wieand HS. A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol 1986;4:1053-7.
59. Cullinan S, Moertel CG, Wieand HS, Schutt AJ, Krook JE, Foley JF, et al. A phase III trial on the therapy of advanced pancreatic carcinoma: evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin and cisplatin. Cancer 1990;65:2207-12.
60. Frey C, Twomey P, Keehn R, Elliott D, Higgins G. Randomized study of 5-FU and CCNU in pancreatic cancer: report of the Veterans Administration Surgical Adjuvant Cancer Chemotherapy Group. Cancer 1981;47:27-31.
61. Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 1985; 253:2061-7.
62. Mallinson CN, Rake MO, Cocking JB. Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. Br Med J 1980;281:1589-91.
63. Brennan MF, Kinsella TJ, Casper ES. Cancer of the pancreas. In: DeVita VT Jr., Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology. 4th ed. Philadelphia: JB Lippincott, 1993:849-82.
64. Rothman H, Cantrell JE Jr., Lokich J, Difino S, Harvey J, Ahlgren J, et al. Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma: a Mid-Atlantic Oncology Program study. Cancer 1991;68:264-8.
65. Redding TW, Schally AV. Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. Proc Natl Acad Sci USA 1984;81:248-52.
66. Zalatnai A, Schally AV. Treatment of the N-nitrosobis(2-oxopropyl)amine-induced pancreatic cancer in Syrian golden hamsters with D-Trp-6-LH-RH and a somatostatin analog RC-160. Cancer Res 1989;49:1810-5.
67. Szende B, Zalatnai A, Schally AV. Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both leuteinizing hormone-releasing hormone and somatostatin. Proc Natl Acad Sci USA 1989; 86:1643-7.
68. Szende B, Srkalovic G, Schally AV, Karoly L, Groot K. Inhibitory effects of analogs of leuteinizing hormone-releasing hormone and somatostatin on pancreatic cancer in hamsters: Events that accompany tumor regression. Cancer 1990;65:2279-90.
69. Keating JJ, Johnson PJ, Wheeler P. A prospective randomised controlled trial of tamoxifen and cyproterone acetate in pancreatic carcinoma. Br J Cancer 1989;60:789-92.
70. Bakkevold KE, Pettersen A, Arnesjo B, Espehaug B. Tamoxifen therapy in unresectable adenocarcinoma of the pancreas and the papilla of Vater. Br J Surg 1990;77:725-30.
71. Wong A, Chan A. Survival benefit of tamoxifen therapy in adenocarcinoma of pancreas. Cancer 1993;71:2200-3.
72. Schally AV. Oncological applications of somatostatin analogs. Cancer Res 1988;48:6977-85.
73. Liebow C, Reilly C, Serrano M, Schally AV. Somatostatin analogs inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc Natl Acad Sci USA 1989;86:2003-7.
74. Ohmura E, Okada M, Onoda N, Kamiya Y, Murakami H, Tsushima T, et al. Insulin-like growth factor 1 and transforming growth factor α as autocrine growth factors in human pancreatic cancer cell growth. Cancer Res 1990;50:103-7.